Ki-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors

Current Eye Research

Volumn 31, Issue 1, 2006, Pages 57-67

  Al Jamal, Rana'a T ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cell proliferation; Ki 67 antigen; Microvascular density; Mortality; Nucleolar morphometry; Uveal melanoma; Vasculogenic mimicry

Indexed keywords

MONOCLONAL ANTIBODY KI 67; SILVER;

ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CHOROID MELANOMA; CILIARY BODY TUMOR; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; EPITHELIOID CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROVASCULATURE; NUCLEOLUS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TISSUE SECTION; UVEA MELANOMA;

CELL NUCLEOLUS; CELL PROLIFERATION; CHOROID NEOPLASMS; CILIARY BODY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MACROPHAGES; MALE; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 31544471204     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500478535     Document Type: Article

References (45)

1. Mikel UV, Engler WF, Perez-Rosario E, et al. A comparative study of morphometric measurements of nucleoli in uveal melanomas from electron micrographs and plastic-embedded and paraffin-embedded sections. Anal Quant Cytol Histol. 1989;11:111-114.
2. Huntington A, Haugan P, Gamel J, McLean I. A simple cytologic method for predicting the malignant potential of intraocular melanoma. PatholRes Practice. 1989;185:631-634.
3. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM. The value of nucleolar organizer regions in uveal melanoma. The Collaborative Ocular Melanoma Study Group. Am J Ophthalmol. 1990;110:527-534.
4. McCurdy J, Gamel J, McLean I. A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H & E slides. Pathol Res Practice. 1991;187:1025-1027.
5. Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Invest Ophthalmol Vis Sci. 1992;33:1919-1922.
6. Søensen FB, Gamel JW, Jensen OA, et al. Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas. APMIS. 1993;101:358-368.
7. Søensen FB, Gamel JW, McCurdy J. Stereologic estimation of nucleolar volume in ocular melanoma: a comparative study of size estimators with prognostic impact. Hum Pathol. 1993;24:513-518.
8. Pe'er J, Rummelt V, Mawn L, et al. Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology. 1994;101:1227-1235.
9. Rummelt V, Folberg R, Woolson RF, et al. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology. 1995;102:844-851.
10. McLean IW, Keefe KS, Burnier MN. Uveal melanoma: comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997;104:777-780.
11. McLean IW, Sibug ME, Becker RL, McCurdy JB. Uveal melanoma: the importance of large nucleoli in predicting patient outcome - an automated image analysis study. Cancer. 1997;79:982-988.
12. Staibano S, Orabona P, Mezza E, et al. Morphometric analysis of AgNORs in uveal malignant melanoma. Anal Quant Cytol Histol. 1998;20:483-492.
13. Baldi G, Baldi F, Maguire M, Massaro-Giordano M. Prognostic factors for survival after enucleation for choroidal melanoma. Int J Oncol. 1998;13:1185-1189.
14. Tuccari G, Gimenez-Mas JA, Fedele F, et al. The AgNOR quantity as prognostic parameter in choroidal melanomas: a standardised analysis. Anal CellPathol. 1999;19:163-168.
15. Seregard S, Spaigberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology. 1998;105:485-491.
16. Tuccari G, GiuffrèG, Gimenez-Mas JA, Öfner D. Morphometric analysis of AgNORs in uveal malignant melanoma. Anal Quant Cytol Histol. 2000;22:183-184.
17. Moshari A, McLean IW. Uveal melanoma: mean of the longest nucleoli measured on silver-stained sections. Invest Ophthalmol Vis Sci. 2001;42:1160-1163.
18. Gerdes J, Lemke H, Baisch H, et al. Cell-cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal-antibody Ki-67. J Immunol. 1984;133:1710-1715.
19. Liang J, Yi C, Schilling H, Li X. [Correlations of Ki-67 expression and histopathologic characteristics in uveal melanomas]. Yan Ke Xue Bao. 2001;17:114-117, 132.
20. Schilling H, Sehu KW, Lee WR. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci. 1997;38:2081-2092.
21. Mooy CM, De JT, Van dH, et al. Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy. Ophthalmology. 1990;97:1275-1280.
22. Bardenstein DS, Char DH, Kaleta-Michaels S, Kroll SM. Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells. Curr Eye Res. 1991;10:479-484.
23. Maniotis AJ, Chen X, Garcia C, et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab invest. 2002;82:1031-1043.
24. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-2480.
25. Makitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999;91:359-367.
26. Fuchs U, Kivelä T, Summanen P, et al. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol. 1992;141:169-181.
27. Munakata S, Hendricks JB. Effect of fixation time and microwave oven heating time on retrieval of the Ki-67 antigen from paraffin-embedded tissue. J Histochem Cytochem. 1993;41:1241-1246.
28. Kivelä T. Immunohistochemical staining followed by bleaching of melanin: a practical method for ophthalmic pathology. Br J Biomed Sci. 1995;52:325-326.
29. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992;23:1298-1305.
30. Folberg R, Rummelt V, Parys-van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
31. Chowers I, Folberg R, Livni N, Pe'er J. p53 Immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid. Curr Eye Res. 2002;24:105-108.
32. Foss AJE, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-2903.
33. Toivonen P, Makitie T, Kujala E, Kivelä T. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1-6.
34. Altman DG. Practical Statistics for Medical Research, 1st ed. London: Chapman & Hall; 1991.
35. Parmar MKB, Machin D. Survival Analysis. A Practical Approach. Chichester: John Wiley & Sons; 1995.
36. Foss AJE, Alexander RA, Hungerford JL, et al. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol. 1997;81:240-246.
37. Hosmer DW Jr, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: John Wiley & Sons; 1999.
38. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
39. Chiquet C, Grange JD, Ayzac L, et al. Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. Br J Ophthalmol. 84:98-102.
40. Chowers I, Folberg R, Livni N, Pe'er J. Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma. Ophthalmology. 2001;108:367-371.
41. Pe'er J, Stefani FH, Seregard S, et al. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC Ocular Oncology Group study. Br J Ophthalmol. 2001;85:1208-1212.
42. Augsburger JJ, Gonder JR, Amsel J, et al. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology. 1984;91:1709-1715.
43. Char DH, Kroll S, Phillips TL. Uveal melanoma. Growth rate and prognosis. Arch Ophthalmol. 1997;115:1014-1018.
44. Plesnicar S, Klanjscek G, Modic S. Actual doubling time values of pulmonary metastases from malignant melanoma. Aust NZ J Surg. 1978;48:23-25.
45. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739-752.